Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX (Botulinum Toxin Type A) for the Prevention of Migraine in Subjects with Episodic Migraine
Sponsor: Abbvie
Phase of Development: Phase III
Study Duration: 48 weeks
Enrollment Status: Open
Principal Investigator: Rajiv Aggarwal, M.D.
Research Contact: 763-302-4162
TV48125-MH-50039 A Long-Term, Prospective, Observational Study to Evaluate the Safety, Including Cardiovascular Safety, of Fremanezumab in Patients with Migraine in Routine Clinical Practice
Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
Phase of Development: Phase IV
Study Duration: 3 years or more
Enrollment Status: Open
Principal Investigator: Rajiv Aggarwal, M.D.
Research Contact: 763-302-4162
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Sponsor: Satsuma Pharmaceuticals
Phase of Development: Phase III
Study Duration: Up to 66 days
Enrollment Status: Open
Principal Investigator: Rajiv Aggarwal, M.D.
Research Contact: 763-302-4162
Allergan 3110-304-002: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome
Sponsor: Abbvie
Phase of Development: Phase III
Study Duration: 16 weeks
Enrollment Status: Closed
Principal Investigator: Rajiv Aggarwal, M.D.
Research Contact: 763-302-4162